| Title |
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
|
|---|---|
| Published in |
Infection and Drug Resistance, November 2013
|
| DOI | 10.2147/idr.s36601 |
| Pubmed ID | |
| Authors |
Amanda Kamali, Mark Holodniy |
| Abstract |
Influenza virus is a pathogen that causes morbidity and mortality worldwide. Whereas vaccination is important for prevention of disease, given its limitations, antiviral therapy is at the forefront of treatment and also plays a role in prevention. Currently, two classes of antiviral medications, the adamantanes and the neuraminidase inhibitors, are approved for treatment. Given the resistance patterns of circulating influenza, adamantanes are not recommended. Within the US, two neuraminidase inhibitors are currently approved for both treatment and prevention, while worldwide there are four available. In this review, we will briefly discuss the epidemiology and pathology of influenza and then discuss neuraminidase inhibitors: their mechanism of action, resistance, development, and future applications. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 89 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 15% |
| Student > Bachelor | 13 | 14% |
| Student > Master | 11 | 12% |
| Researcher | 10 | 11% |
| Professor | 8 | 9% |
| Other | 24 | 26% |
| Unknown | 11 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 23% |
| Agricultural and Biological Sciences | 18 | 20% |
| Biochemistry, Genetics and Molecular Biology | 14 | 15% |
| Chemistry | 9 | 10% |
| Immunology and Microbiology | 4 | 4% |
| Other | 11 | 12% |
| Unknown | 14 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2023.
All research outputs
#1,581,138
of 24,220,739 outputs
Outputs from Infection and Drug Resistance
#58
of 1,899 outputs
Outputs of similar age
#14,907
of 218,789 outputs
Outputs of similar age from Infection and Drug Resistance
#1
of 7 outputs
Altmetric has tracked 24,220,739 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,899 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 218,789 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them